Novo Nordisk (NVO) is a Top Dividend Stock Right Now: Should You Buy?

Company Overview - Novo Nordisk (NVO) is a pharmaceutical company headquartered in Bagsvaerd, operating in the Medical sector [3] - The stock has experienced a price decline of 21.47% since the beginning of the year [3] Dividend Information - Novo Nordisk currently pays a dividend of $0.82 per share, resulting in a dividend yield of 2.43%, which is higher than the Large Cap Pharmaceuticals industry's yield of 2.37% and the S&P 500's yield of 1.6% [3] - The company's annualized dividend of $1.64 has increased by 59.8% compared to the previous year [4] - Over the last five years, Novo Nordisk has raised its dividend five times, achieving an average annual increase of 22.48% [4] - The current payout ratio is 22%, indicating that the company pays out 22% of its trailing 12-month earnings per share as dividends [4] Earnings Growth Expectations - For the fiscal year, Novo Nordisk anticipates solid earnings growth, with the Zacks Consensus Estimate for 2025 at $3.89 per share, reflecting an expected increase of 18.60% from the previous year [5] Investment Appeal - Novo Nordisk is considered a compelling investment opportunity due to its attractive dividend and strong Zacks Rank of 2 (Buy) [7]